

EDCTP portfolio: medical interventions against poverty-related infectious diseases

(2014-2019)

Phase Ia/b	Phase IIa/b	Phase III	Phase IV	Non-phase diagnostic trial	Observational study
VirTUAL Uganda, South Africa	CAPRISA 018 South Africa	POR TB South Africa, Tanzania	CHAPS South Africa, Uganda	PREGART Ethiopia, Uganda	DREAMM Cameroon, Malawi, Tanzania
MoxiMultiDoseMod DR Congo, Ghana	PROMISE-EPI Burkina Faso, Zimbabwe	MMVC Burkina Faso, Kenya, Sierra Leone, Tanzania	AMBITION-cm Botswana, Malawi, South Africa, Uganda, Zimbabwe	5FC HIV-Crypto Ethiopia, Uganda	DIAMA Benin, Cameroon, DR Congo, Ethiopia, Guinea, Mali, Nigeria, Rwanda, Senegal
PEAU-EBOV-RDC	PanACEA Ethiopia, Malawi, Mali, Mozambique, Nigeria, Rwanda, South Africa, Senegal, Tanzania	PfTBV Burkina Faso, Guinea, Liberia, Mali	CHAPAS-4 Uganda, Zambia, Zimbabwe	TREATS South Africa, Zambia	Stop TB/HIV at one Ethiopia, Nigeria
CAPo12 SAMBA Trial South Africa, Zambia	CLICK-TB South Africa	MIMVac-Africa Burkina Faso, Gabon, Mozambique, Tanzania	BREATHER Plus Kenya, South Africa, Uganda, Zimbabwe	PEOPLE Comoros, Madagascar	Screen TB Ethiopia, The Gambia, Namibia, South Africa, Uganda
MMVC The Gambia, Kenya	StatinTB South Africa	PREV-PKDL Ethiopia, Kenya, Sudan, Uganda	VITALITY Zambia, Zimbabwe	FibroScHot Uganda	DIAMA Benin, Cameroon, DR Congo, Ethiopia, Guinea, Mali, Nigeria, Rwanda, Senegal
PfTBV Burkina Faso, Guinea, Liberia, Mali	Simplici-TB Gabon, Malawi, Mozambique, South Africa, Tanzania, Uganda	ShigOraVax Burkina Faso, Zambia	META TRIAL Tanzania	PEP4LEP Ethiopia, Mozambique, Tanzania	TriageTB The Gambia, South Africa, Uganda
MIMVac-Africa Burkina Faso, Gabon, Mozambique, Tanzania	DATURA Cameroon, Guinea, Tanzania, Uganda	PREPARE South Africa, Uganda	INTENSE-TBM Cote d'Ivoire, Madagascar, South Africa, Uganda	PediCAP South Africa, Uganda, Zambia, Zimbabwe	
ETEC Vaccine Efficacy The Gambia, Zambia	WANECAM II Burkina Faso, Gabon, Mali, Niger	PREVAC-UP Guinea, Liberia, Mali, Sierra Leone	PROTID Tanzania, Uganda	NIFTY Senegal, Uganda	
ShigOraVax Burkina Faso, Zambia	PAMAFRICA Burkina Faso, Gabon, Mozambique, Uganda	WANECAM II Burkina Faso, Gabon, Mali, Niger	IMPROVE Kenya, Malawi, Tanzania	LIFE Study Mozambique, Tanzania	
	SINDOFO Burkina Faso, Kenya, Mozambique	IMPROVE-2 Kenya, Malawi	IMPROVE-2 Kenya, Malawi		
	HAT-r-ACC Malawi, Uganda, Zambia	MAMAH Gabon, Mozambique	ASAAP Benin, Burkina Faso, Gabon, Ghana, Mali		
	EMPIRICAL Cote d'Ivoire, Malawi, Mozambique, Uganda, Zambia, Zimbabwe	ASAAP Benin, Burkina Faso, Gabon, Ghana, Mali	PYRAPREG Burkina Faso, DR Congo, The Gambia, Mali, Mozambique		
	GREAT Kenya, Uganda, Zambia	MAMAH Gabon, Mozambique	MoxiMultiDoseMod DR Congo, Ghana		
	Neo bnAb Mozambique, Tanzania	ASAAP Benin, Burkina Faso, Gabon, Ghana, Mali	HAT-r-ACC Malawi, Uganda, Zambia		
	PrEPVacc Mozambique, Tanzania, Uganda	PYRAPREG Burkina Faso, DR Congo, The Gambia, Mali, Mozambique			
	MTBVAC-Newborns South Africa	MoxiMultiDoseMod DR Congo, Ghana			
		HAT-r-ACC Malawi, Uganda, Zambia			

Intervention	Other	Disease	Population
Drugs	Product-focused implementation research	HIV and HIV associated infections	Adults (18yr and above)
Vaccines		Tuberculosis	Adolescents (10yr-17yr)
Diagnostics		Malaria	Children (2yr-9yr)
Other		Neglected infectious diseases	Infants (above 1mo-1yr)
Product-focused implementation research		Emerging diseases	Pregnant women and/or newborns (birth to 1mo)
		Lower respiratory tract infections	
		Diarrhoeal diseases	